RxDoctor Payments Data

Eloise Palmisano

Psychiatric/Mental Health · Saratoga Springs, NYNPI 1730404021

Payments from drug & device makers

$1,132in general payments, 2019–2025

Across 33 payments — averaging $34.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$391
  • Johnson & Johnson$284
  • Novo Nordisk$194
  • Ultragenyx Pharmaceutical Inc.$122
  • Janssen Scientific Affairs, LLC$115
  • Bausch Health US, LLC$15
  • plus $11 from 1 others

What the payments were for

  • Consulting fees$11510%
  • Food & beverage$1,01790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,132 in reported general payments places this provider in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$39,534
Medicare patients
20
Services billed
573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl105$149,860
VyvanseLisdexamfetamine Dimesylate23$9,366
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine32$1,227
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$825
Lurasidone Hcl11$324
Lorazepam23$270
Bupropion XlBupropion Hcl13$261
Alprazolam39$211
Zolpidem Tartrate27$187
Fluoxetine Hcl51$185
Gabapentin15$134
Trazodone Hcl21$94
Sertraline Hcl13$89
Lamotrigine13$77

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$284$149,860105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Saratoga Springs

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →